A 6-year-old boy with an atypical liver neoplasm harboring a novel RPS6KA3 variant

Lab Med. 2024 May 2;55(3):391-393. doi: 10.1093/labmed/lmad061.

Abstract

Pediatric hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are primary liver malignant neoplasms with 5-year event-free survival of >80% and <30%, respectively. In these patients, α-fetoprotein levels can guide surgical intervention and monitor disease progression. Although histology and immunohistochemical stains support diagnosis, genetic testing can elucidate mechanisms that drive pathogenesis. Pediatric HBL and HCC harbor well-characterized molecular signatures such as alterations in CTNNB1, TERT, and AXIN1 that alter the Wnt/β-catenin pathway. Approximately 8% of individuals with HCC harbor RPS6KA3 variants that appear with other gene mutations. Herein, we report a novel solitary pathogenic RPS6KA3 variant finding in a 6-year-old boy whose final diagnosis was hepatocellular malignant neoplasm, not otherwise specified.

Keywords: RPS6KA3 mutation; analytical measurement range; carcinoma; hepatoblastoma; hepatocellular; hepatocellular malignant neoplasm not otherwise specified; α-fetoprotein.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / pathology
  • Child
  • Hepatoblastoma / diagnosis
  • Hepatoblastoma / genetics
  • Hepatoblastoma / pathology
  • Humans
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / pathology
  • Male
  • Ribosomal Protein S6 Kinases, 90-kDa* / genetics
  • Ribosomal Protein S6 Kinases, 90-kDa* / metabolism

Substances

  • Ribosomal Protein S6 Kinases, 90-kDa
  • ribosomal protein S6 kinase, 90kDa, polypeptide 3